Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR-EXO + PP@Cur
- Development stage
- Preclinical
- Lead developer
- Capital Medical University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
PR-EXO + PP@Cur is a **nanocarrier combination drug** designed for synergistic therapy of neurodegenerative diseases, especially **Parkinson’s disease**. It integrates **mesenchymal stem cell (MSC)-derived exosomes** (PR-EXO) as the carrier and a **curcumin-loaded nanoparticle complex** (PP@Cur). The formulation navigates multiple biological membranes and directly releases curcumin into the cytoplasm of target cells after **intranasal administration**. Its mechanism encompasses reducing α-synuclein aggregates, promoting neuronal function recovery, and alleviating neuroinflammation. PR-EXO + PP@Cur demonstrates enhanced drug accumulation at disease sites and significantly improves motor function and coordination in Parkinson's disease animal models[1][3].
- Brand names
- PR-EXO + PP@Cur
- Other names
- PR-EXO/PP@CurPR-EXO + PP@Cur
02
Targets
SNCA (Alpha-synuclein)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on PR-EXO + PP@Cur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR-EXO + PP@Cur.